SCHEMBL6855264

SCHEMBL6855264

COC(=O)C(O)Cc1c[nH]c2ccccc12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.69
MEN1 O00255 2/20 0.60
KMT2A Q03164 2/20 0.60
HCRTR1 O43613 1/20 0.60
KDM4E B2RXH2 3/20 0.59
MAPT P10636 2/20 0.59
POLB P06746 2/20 0.59
APAF1 O14727 1/20 0.59
RECQL P46063 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
MIF P14174 1/20 0.59
ALOX15 P16050 1/20 0.56
LMNA P02545 1/20 0.56
MPO P05164 1/20 0.56
TSHR P16473 1/20 0.56
BLM P54132 1/20 0.56
PMP22 Q01453 1/20 0.56
HIF1A Q16665 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
PKM P14618 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13790109 1.00 SMN1; SMN2 (0.69) SMN1; SMN2MEN1KMT2AHCRTR1KDM4E
SCHEMBL30912053 1.00 SMN1; SMN2 (0.69) SMN1; SMN2MEN1KMT2AHCRTR1KDM4E
SCHEMBL29769924 1.00 SMN1; SMN2 (0.69) SMN1; SMN2MEN1KMT2AHCRTR1KDM4E
SCHEMBL30682399 1.00 SMN1; SMN2 (0.69) SMN1; SMN2MEN1KMT2AHCRTR1KDM4E
SCHEMBL30912054 1.00 SMN1; SMN2 (0.69) SMN1; SMN2MEN1KMT2AHCRTR1KDM4E
SCHEMBL6278978 0.87 SMN1; SMN2 (0.68) SMN1; SMN2MEN1KMT2AKDM4EMAPT
SCHEMBL9053137 0.86 SMN1; SMN2 (0.69) SMN1; SMN2MEN1KMT2AKDM4EMAPT
SCHEMBL6286138 0.86 MEN1 (0.60) SMN1; SMN2MEN1KMT2AHCRTR1KDM4E
SCHEMBL8258964 0.86 KDM4E (0.72) SMN1; SMN2MEN1KMT2AHCRTR1KDM4E
SCHEMBL10276380 0.86 KDM4E (0.72) SMN1; SMN2MEN1KMT2AHCRTR1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3749635-B1 PROCESS OF PRODUCING ALPHA-HYDROXY COMPOUNDS AND USES THEREOF HALDOR TOPSOE AS (DK) 2022-07-13 EP disclosed
US-20210045414-A1 PROCESS OF PRODUCING ALPHA-HYDROXY COMPOUNDS AND USES THEREOF HALDOR TOPSØE A/S (DK) 2021-02-18 US disclosed
WO-2019154624-A1 PROCESS OF PRODUCING ALPHA-HYDROXY COMPOUNDS AND USES THEREOF HALDOR TOPSØE A/S (DK) 2019-08-15 WO disclosed
US-20140315956-A1 SMALL MOLECULE INHIBITORS OF IL-6 AND USES THEREOF NATIONWIDE CHILDREN'S HOSPITAL (US) 2014-10-23 US disclosed
WO-2013019690-A1 SMALL MOLECULE INHIBITORS OF IL-6 AND USES THEREOF THE OHIO STATE UNIVERSITY (US) 2013-02-07 WO disclosed
US-6831175-B2 Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine ABBOTT LABORATORIES 2004-12-14 US disclosed
EP-1463505-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER Abbott Laboratories (US) 2004-10-06 EP disclosed
US-20030199511-A1 Kinase inhibitors ABBVIE INC. 2003-10-23 US disclosed
US-20030187026-A1 Kinase inhibitors ABBOTT LABORATORIES 2003-10-02 US disclosed
WO-2003051366-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER ABBOTT LABORATORIES (US) 2003-06-26 WO disclosed
US-5780498-A PEPTIDE DERIVATIVES FOR CARDIOVASCULAR AND BRAIN DISORDERS CIBA-GEIGY JAPAN LIMITED (JP) 1998-07-14 US disclosed
EP-0728145-A1 ENDOTHELIN RECEPTOR ANTAGONISTS Ciba-Geigy Japan Limited (JP) 1996-08-28 EP disclosed
WO-1995012611-A1 ENDOTHELIN RECEPTOR ANTAGONISTS JAPAT LTD. (CH) 1995-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187026-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 SMN1; SMN2 2830/4885MEN1 1169/4885KMT2A 1640/4885
US-20140315956-A1 SMALL MOLECULE INHIBITORS OF IL-6 AND USES THEREOF IL6, STAT3, JAK2 SMN1; SMN2 4654/4885MEN1 3590/4885KMT2A 2536/4885
US-20030199511-A1 Kinase inhibitors MAP3K20, MAP3K19, MAP3K1 SMN1; SMN2 2830/4885MEN1 1169/4885KMT2A 1640/4885
US-20210045414-A1 PROCESS OF PRODUCING ALPHA-HYDROXY COMPOUNDS AND USES THEREOF HAAO, CYP8B1, PAH SMN1; SMN2 4057/4885MEN1 2912/4885KMT2A 2648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.